Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

01-11-2016 | Sarcoma | Article

An Update on Kaposi’s Sarcoma: Epidemiology, Pathogenesis and Treatment

Journal: Dermatology and Therapy

Authors: Paul Curtiss, Lauren C. Strazzulla, Alvin E. Friedman-Kien

Publisher: Springer Healthcare

Login to get access

Abstract

Kaposi’s sarcoma is an angioproliferative neoplasm which has undergone considerable epidemiologic change since the original description by Moritz Kaposi in the late 1800s. This opportunistic neoplasm gained widespread notoriety within the US during the height of the AIDS epidemic, where it was frequently found co-occurring with opportunistic infections. With the advent of modern antiretroviral therapies, as well as an increasing number of individuals on immunosuppression for autoimmune disease or organ transplantation, the landscape of the immunocompromised individual has changed. It is now important for clinicians to be mindful of Kaposi’s sarcoma manifesting in a growing variety of clinical contexts.
Literature
1.
Friedman-Kien AE, et al. Kaposis sarcoma and Pneumocystis pneumonia among homosexual men–New York City and California. Morb Mortal Wkly Rep. 1981;30(25):305–8.
2.
Friedman-Kien AE. Kaposi’s sarcoma: an opportunistic neoplasm. J Investig Dermatol. 1984;82(5):446–8.CrossRefPubMed
3.
Dourmishev LA, et al. Molecular genetics of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) epidemiology and pathogenesis. Microbiol Mol Biol Rev. 2003;67(2):175–212.CrossRefPubMedPubMedCentral
4.
Martin JN, et al. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med. 1998;338(14):948–54.CrossRefPubMed
5.
Archibald CP, et al. Risk factors for Kaposi’s sarcoma in the Vancouver Lymphadenopathy-AIDS Study. J Acquir Immune Defic Syndr. 1990;3(9):S18–23.PubMed
6.
Jones JL, et al. Incidence and trends in Kaposi’s sarcoma in the era of effective antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;24(3):270–4.CrossRefPubMed
7.
Eltom MA, et al. Trends in Kaposi’s sarcoma and non-Hodgkin’s lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst. 2002;94(16):1204–10.CrossRefPubMed
8.
Kaposi M. Idiopathisches multiples pigmentsarkom der haut. Arch Dermatol Syph. 1872;4:265–73.CrossRef
9.
Hengge UR, et al. Update on Kaposi’s sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis. 2002;2(5):281–92.CrossRefPubMed
10.
Geddes M, et al. Kaposi’s sarcoma in Italy before and after the AIDS epidemic. Br J Cancer. 1994;69(2):333.CrossRefPubMedPubMedCentral
11.
Kaminer B, Murray JF. Sarcoma idiopathicum multiplex haemorrhagicum of Kaposi, with special reference to its incidence in the South African Negro, and two case reports. S Afr J Clin Sci. 1950; 1(1):1.
12.
Wabinga HR, et al. Cancer in Kampala, Uganda, in 1989–91: changes in incidence in the era of AIDS. Int J Cancer. 1993;54(1):26–36.CrossRefPubMed
13.
Jalbert E, DiGiovanni R, Worth R. Stage-IV Kaposi’s sarcoma during abatacept therapy: a case report. Rheumatology (Sunnyvale). 2015;5:144.
14.
Rady PL, Hodak E, Yen A et al. Detection of human herpesvirus-8 DNA in Kaposi’s sarcomas from iatrogenically immunosuppressed patients. J Am Acad Dermatol. 1998;38:429–37.CrossRefPubMed
15.
Yoo S, et al. A case of exogenous corticosteroid-induced Kaposi’s sarcoma that developed after a cure of endogenous hypercortisolism. Int J Clin Pharm. 2015;37(6):988–91.CrossRefPubMed
16.
Peterman TA, Jaffe HW, Beral V. Epidemiologic clues to the etiology of Kaposi’s sarcoma. Aids. 1993;7(5):605–12.CrossRefPubMed
17.
Zavos G, et al. Clinicopathological aspects of 18 Kaposi’s sarcoma among 1055 Greek renal transplant recipients. Artif Organs. 2004;28(6):595–9.CrossRefPubMed
18.
Hosseini-Moghaddam SM, et al. Post renal transplantation Kaposi’s sarcoma: a review of its epidemiology, pathogenesis, diagnosis, clinical aspects, and therapy. Transpl Infect Dis. 2012;14(4):338–45.CrossRefPubMed
19.
Detroyer D, et al. Resolution of diffuse skin and systemic Kaposi’s sarcoma in a renal transplant recipient after introduction of everolimus: a case report. Transpl Infect Dis. 2015;17(2):303–7.CrossRefPubMed
20.
Stallone G, et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med. 2005;352(13):1317–23.CrossRefPubMed
21.
Friedman-Kien AE, et al. Kaposi’s sarcoma in HIV-negative homosexual men. Lancet. 1990;335(8682):168–9.CrossRefPubMed
22.
Serraino D, et al. HIV transmission, and Kaposi’s sarcoma among European women. Aids. 1995;9(8):971–4.CrossRefPubMed
23.
Russo JJ, et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci USA 1996;93(25):14862–7.CrossRefPubMedPubMedCentral
24.
Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi’s sarcoma and a subset of angiosarcomas. Mod Pathol. 2002;15(4):434–40.CrossRefPubMed
25.
Ensoli B, et al. Biology of Kaposi’s sarcoma. Eur J Cancer. 2001;37(10):1251–69.CrossRefPubMed
26.
Stürzl M, et al. Human herpesvirus-8 and Kaposi’s sarcoma: relationship with the multistep concept of tumorigenesis. Adv Cancer Res. 2001;81:125–59.CrossRefPubMed
27.
Ensoli B, et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi’s sarcoma. Nature. 1994;371(6499):674–80.CrossRefPubMed
28.
Gallo RC. The enigmas of Kaposi’s sarcoma. Science. 1998;282(5395):1837–9.CrossRefPubMed
29.
Von Roenn JH, Cianfrocca M. Treatment of Kaposis sarcoma. In: Sparano JA, editor. HIV & HTLV-I associated malignancies. New York: Springer; 2001. p. 127–48.CrossRef
30.
Brambilla L, et al. Intralesional vincristine as first-line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study in 151 patients. Br J Dermatol. 2010;162(4):854–9.CrossRefPubMed
31.
Di Trolio R, et al. Role of pegylated lyposomal doxorubicin (PLD) in systemic Kaposi’s sarcoma: a systematic review. Int J Immunopathol Pharmacol. 2006;19(2):253–63.PubMed
32.
Di Lorenzo G, et al. Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi’s sarcoma: a multicenter study. J Investig Dermatol. 2008;128(6):1578–80.CrossRefPubMed
33.
Weshler Z, et al. Megavoltage radiotherapy using water bolus in the treatment of Kaposi’s sarcoma. Int J Radiat Oncol Biol Phys. 1986;12(11):2029–32.CrossRefPubMed
34.
Moosa MR. Kaposi’s sarcoma in kidney transplant recipients: a 23-year experience. QJM. 2005;98(3):205–14.CrossRefPubMed
35.
Connick E, et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy. Clin Infect Dis. 2004;39(12):1852–5.CrossRefPubMed
36.
Bower M, et al. Immune reconstitution inflammatory syndrome associated with Kaposi’s sarcoma. J Clin Oncol. 2005;23(22):5224–8.CrossRefPubMed